Remicade (Infliximab) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Remicade

Crohn's Disease »

What is Crohn's disease?

Crohn's disease (also spelled Crohn disease) is a chronic inflammatory disease of the intestines. It primarily causes ulcerations (breaks in the lining) of the small and large intestines, but can affect the digestive system anywhere from the mouth to the anus. It is named after the physician who described the disease in 1932. It also is called granulomatous enteritis or colitis, regional enteritis, ileitis, or terminal ileitis.

Crohn's disease is related closely to another chronic inflammatory condition that involves only the colon called ulcerative colitis. Together, Crohn's disease and ulcerative colitis are frequently referred to as inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's disease have no medical cure. Once the diseases begin, they tend to fluctuate between periods of inactivity (remission) and activity (relapse).

Inflammatory bowel disease affects approximately 500,000 to two million peop...

Read the Crohn's Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Remicade User Reviews >>

Remicade

Rheumatoid Arthritis Slideshow Pictures

Take the RA Quiz

Rheumatoid Arthritis Exercises Slideshow Pictures

font size

OVERDOSE

Single doses up to 20 mg/kg have been administered without any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.

CONTRAINDICATIONS

REMICADE at doses > 5 mg/kg should not be administered to patients with moderate to severe heart failure. In a randomized study evaluating REMICADE in patients with moderate to severe heart failure (New York Heart Association [NYHA] Functional Class III/IV), REMICADE treatment at 10 mg/kg was associated with an increased incidence of death and hospitalization due to worsening heart failure [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].

REMICADE should not be re-administered to patients who have experienced a severe hypersensitivity reaction to REMICADE. Additionally, REMICADE should not be administered to patients with known hypersensitivity to inactive components of the product or to any murine proteins.

Last reviewed on RxList: 10/10/2011
This monograph has been modified to include the generic and brand name in many instances.